Amphista Therapeutics received IND clearance from the FDA for AMX-883, an orally bioavailable BRD9 degrader intended for acute myeloid leukemia (AML). The company expects a phase 1 trial to begin in the second half of this year in patients with relapsed or refractory AML and high-risk myelodysplastic syndrome. AMX-883 adds to the growing pipeline of targeted protein degradation approaches in hematologic malignancies, aiming to modulate tumor-driving epigenetic dependencies through BRD9 degradation. Amphista did not provide additional expansion-cohort or combination details in the clearance report. The clearance sets up the clinical test of pharmacology, safety, and early efficacy as degrader platforms compete for attention in AML’s late-line treatment landscape.